SG
APLS

Stonnington Group’s Apellis Pharmaceuticals APLS Stock Holding History

Stonnington Group’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		$744K Buy
+9,400
New +$542K 0.19% 115
2022
Q1 		– Sell
-10,000
Closed -$412K – 237
2021
Q4 		$412K Buy
+10,000
New +$394K 0.09% 180
2021
Q3 		– Sell
-8,000
Closed -$524K – 257
2021
Q2 		$524K Buy
+8,000
New +$413K 0.12% 170

Other funds holding APLS

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Stonnington Group's APLS Position: Q1 2023 in Review

Stonnington Group opened a new position in Apellis Pharmaceuticals (APLS) in Q1 2023: 9,400 shares worth $744K. The stake represents 0.19% of the portfolio and ranks #115 among its holdings. This is a return to the name: Stonnington Group previously reported a position in APLS as recently as Q4 2021.

Stonnington Group first reported a position in APLS in Q2 2021 and has held it in 3 quarters since. 281 funds tracked by Wall St. Rank hold APLS as of Q1 2023.

  • Stonnington Group held 9,400 shares of Apellis Pharmaceuticals worth $744K as of Q1 2023.
  • Apellis Pharmaceuticals was a new Stonnington Group position in Q1 2023.
  • Apellis Pharmaceuticals made up 0.19% of Stonnington Group's portfolio in Q1 2023, its #115 holding.
  • Stonnington Group first reported a position in Apellis Pharmaceuticals in Q2 2021 and has held it in 3 quarters since.
  • 281 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2023.

Based on Stonnington Group's 13F filing for Q1 2023, filed 14 Apr 2023.